Holen Sie sich die Stockscreener-App
42.64
3.39%
1.40
Handel nachbörslich:
42.64
Schlusskurs vom Vortag:
$41.24
Offen:
$41.31
24-Stunden-Volumen:
1.08M
Relative Volume:
1.46
Marktkapitalisierung:
$2.39B
Einnahmen:
$651.97M
Nettoeinkommen (Verlust:
$59.71M
KGV:
39.87
EPS:
1.0696
Netto-Cashflow:
$172.03M
1W Leistung:
+0.47%
1M Leistung:
+28.74%
6M Leistung:
+7.87%
1J Leistung:
+26.72%
1-Tages-Spanne:
$41.01
$42.96
1-Wochen-Bereich:
$40.26
$42.96
52-Wochen-Spanne:
$29.16
$43.62
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Firmenname
Supernus Pharmaceuticals Inc
Sektor
Telefon
301-838-2500
Adresse
9715 KEY WEST AVENUE, ROCKVILLE, MD
Vergleichen Sie SUPN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
42.64 | 2.27B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
152.44 | 66.38B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 46.20B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.99B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 19.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.72 | 13.63B | 2.99B | 1.21B | 1.13B | 25.06 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Fortgesetzt | Jefferies | Buy |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-04-13 | Hochstufung | Jefferies | Hold → Buy |
| 2020-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Fortgesetzt | Jefferies | Hold |
| 2019-11-08 | Herabstufung | Berenberg | Buy → Hold |
| 2019-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2019-11-06 | Herabstufung | Jefferies | Buy → Hold |
| 2018-11-12 | Bestätigt | B. Riley FBR | Buy |
| 2018-01-18 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-08 | Hochstufung | Stifel | Hold → Buy |
| 2017-10-19 | Eingeleitet | FBR & Co. | Buy |
| 2017-09-19 | Herabstufung | Stifel | Buy → Hold |
| 2017-07-17 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Eingeleitet | Janney | Neutral |
| 2017-06-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Hochstufung | Jefferies | Hold → Buy |
| 2015-11-05 | Bestätigt | Northland Capital | Outperform |
| 2015-10-28 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
These Three Healthcare Cos. Could Inject New Life Into an Ailing Portfolio - TheStreet Pro
Short Term Trend Reversal in Supernus Pharmaceuticals Inc. Possible [Portfolio Gains Report]Free Daily Stock Momentum Reports - 선데이타임즈
Statutory Profit Doesn't Reflect How Good Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are - Yahoo Finance
5 Insightful Analyst Questions From Supernus Pharmaceuticals’s Q2 Earnings Call - Yahoo Finance
Here’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN) - MSN
Supernus Pharmaceuticals shares rise 1.48% intraday after Lotus Pharmaceuticals reported a 6% revenue increase in the first half of 2025. - AInvest
Supernus Announces Second Quarter 2025 Financial Results - ADVFN Brasil
RSI + MACD Show Convergence for Supernus Pharmaceuticals Inc.High Conviction Intraday Stock Signals Detected - metal.it
CEO’s Major Stock Sale Shakes Up Supernus Pharmaceuticals - TipRanks
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q2 2025 Earnings Call Transcript - Insider Monkey
Supernus Pharmaceuticals Shares Dip Amid Growth Plans - TipRanks
Supernus Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges - TipRanks
SUPN Stock Surge: What’s Driving It? - StocksToTrade
Why Are Supernus Pharmaceuticals (SUPN) Shares Soaring Today - Yahoo Finance
Supernus Pharmaceuticals price target raised to $43 from $38 at Stifel - Investing.com Canada
Supernus Pharmaceuticals (SUPN) Price Target Raised by Cantor Fi - GuruFocus
Supernus Pharmaceuticals stock hits 52-week high at 40.3 USD - Investing.com
Supernus Pharmaceuticals stock hits 52-week high at 40.3 USD By Investing.com - Investing.com Australia
Supernus 2025 Q2 Earnings Mixed Results as Net Income Grows 13% - AInvest
Supernus Pharmaceuticals Q2 CY2025 Financial Results: Exceeding Market ExpectationsNews and Statistics - IndexBox
Supernus: Q2 Earnings Snapshot - New Haven Register
Supernus Pharmaceuticals Inc (SUPN) Q2 2025 Earnings Call Highlights: Innovation and Strategic ... - Yahoo Finance
Supernus Pharmaceuticals Inc (SUPN) Q2 2025 Earnings Call Highlights: Innovation and Strategic ... By GuruFocus - Investing.com Canada
Supernus Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Supernus Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Supernus Pharmaceuticals Delivers Growth With Qelbree And GOCOVRI - Finimize
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
Supernus Pharmaceuticals Q2 2025: Navigating Contradictions in ONAPGO, Qelbree, and ZURZUVAE Growth - AInvest
Supernus Pharmaceuticals shares rise 4.21% after-hours after reporting Q2 revenue of $165.5M, beating estimates. - AInvest
Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales - TradingView
Supernus Pharmaceuticals Q2 Earnings Rise, Revenue Falls; 2025 Revenue Guidance Boosted - MarketScreener
Earnings call transcript: Supernus Q2 2025 revenue beats forecast, EPS misses By Investing.com - Investing.com South Africa
Earnings call transcript: Supernus Q2 2025 revenue beats forecast, EPS misses - Investing.com
Supernus Pharmaceuticals Q2 revenue falls - MarketScreener
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
SUPERNUS PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Supernus Pharmaceuticals Announces Q2 2025 Financial Results and Acquisition of Sage Therapeutics - Quiver Quantitative
Supernus Pharmaceuticals (NASDAQ:SUPN) Earnings Report PreviewNews and Statistics - IndexBox
Supernus Pharmaceuticals (SUPN) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
When is Supernus Pharmaceuticals Inc. stock expected to show significant growthExceptional growth trajectory - Jammu Links News
What makes Supernus Pharmaceuticals Inc. stock price move sharplyAchieve superior returns through strategic trading - Jammu Links News
Is Supernus Pharmaceuticals Inc. a growth stock or a value stockFree Investment Timing Strategies - Jammu Links News
What are the technical indicators suggesting about Supernus Pharmaceuticals Inc.Rapid market gains - Jammu Links News
Why is Supernus Pharmaceuticals Inc. stock attracting strong analyst attentionUnlock daily market insights for better trades - Jammu Links News
Should I hold or sell Supernus Pharmaceuticals Inc. stock in 2025Build wealth steadily with proven methods - Jammu Links News
What are analysts’ price targets for Supernus Pharmaceuticals Inc. in the next 12 monthsStay ahead with daily expert stock picks - Jammu Links News
Is Supernus Pharmaceuticals Inc. a good long term investmentSuperior portfolio returns - Jammu Links News
Supernus Acquires Sage Therapeutics to Strengthen Neuropsychiatric Portfolio - AInvest
Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Supernus Pharmaceuticals Inc-Aktie (SUPN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Khattar Jack A. | President, CEO |
Aug 06 '25 |
Sale |
42.02 |
140,000 |
5,883,360 |
1,030,183 |
4.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):